China's NPC meeting opens with healthcare at top of agenda

China’s major political bodies, the Chinese People’s Political Consultative Conference (CPPCC) and the National People’s Congress (NPC), began their delayed annual meetings today in Beijing. The“Two Sessions”meeting kicked off with several proposals impacting the healthcare industry.

Premier Li Keqiang: drive up health infrastructure and primary medical services

Premier Li's government work report included pledges to pump up public health infrastructure, based around a“life first” principle and motto. This will include reforms to the disease prevention and control system, improvements to infectious diseases reporting and early warning system, and the prompt and transparent release of epidemic information. The country also vows to make good use of special anti-epidemic national funding, and increase investment in research and development of vaccines, drugs and rapid detection kits, medical facilities for epidemic prevention and treatment, mobile laboratories, and emergency supply security, primary health and epidemic prevention.

The per capita financial subsidy for resident Basic Medical Insurance (BMI) will be increased by RMB 30 (USD 4.20), and direct out-patient payment settlement between provinces will be piloted. Medical institutions hit by the COVID-19 pandemic will be supported financially. Traditional Chinese medicine (TCM) will continue to receive special support.

Yu Luming: HPV vaccines involved in national immunization

CPPCC member and Director of Beijing Municipal Medical Insurance Bureau Yu Luming proposed that human papillomavirus (HPV) vaccines should be added to the national immunization plan, and made freely available to girls aged 9-14 in order to minimize the life-threatening cervical cancer caused by HPV.

The low rate of HPV vaccination among women of appropriate age in China is mainly due to lack of vaccine suppliers, limited supply capacity, and exorbitant prices of imported vaccines. The first batch of domestic bivalent HPV vaccines was released by the National Medical Products Administration (NMPA) in May 2020, at half the price of similar imported vaccines.

Dr Ding Lieming: secure emergency supplies of cancer drugs

Betta Pharma CEO and National People’s Congress deputy Ding Lieming proposed that a batch of targeted cancer drugs and others with clear efficacy addressing urgent clinical needs should be included in the national emergency supply security system. Once a major public event occurs, these drugs can be allocated uniformly and supplied alongside with disaster relief materials to ensure normal and timely medication for cancer patients.


Related news
China’s Betta Pharmaceuticals Co., Ltd (300558.SZ) released its 2020 Q1 financial report.
China’s Betta Pharmaceuticals Co., Ltd (300558.SZ) released its 2019 financial report.
China’s Beijing Mabworks Biotech Co., Ltd, reportedly raised RMB 1.13 billion (USD 160 million) via Series C1 and C2 financing rounds.
The Center for Drug Evaluation (CDE) released two notifications setting out clinical study standards biosimilar developers of bevacizumab (Roche’s Avastin) and trastuzumab (Roche's Herceptin).
China’s Betta Pharmaceuticals Co., Ltd (300558.SZ) announced plans to raise RMB 1 billion (USD 144 million) via a private placement of A shares.
  • 1583300744454
  • China
  • Deals
Recent news
Colombia’s Financial Corporation for Territorial Development (FINDETER), a state-owned banking corporation, last week announced a COP 256 billion (USD 68 million) credit line for health plans and health institutions hit by the global economic downturn.
Hebei's provincial Healthcare Commission bureau released a notice setting out a broad range of medical reforms, linking together medical care, medical insurance, pharmaceuticals pricing, and in particular centralized drug procurement.
Carlos da Costa, an officer at Brazil’s Ministry of Economy (MoE), last week commented on the postponement in the allowed increase in drug prices for 2020, a measure that was announced in the end of March and is aimed at supporting patients during the COVID-19 outbreak.
China is ramping up appointment diagnosis and treatment systems and intelligent hospital infrastructure.
Argentine drug maker Elea-Phoenix has purchased two established products from Sanofi, continuing the French firm’s divestment of its over-the-counter (OTC) drugs and expanding on a previous deal between the two firms announced in March this year.
Wu Depei, CPPCC member and hematology department director at the First Affiliated Hospital of Soochow University, suggested immune thrombocytopenia (ITP) be included in medical insurance schemes.
China-based Lee’s Pharmaceutical Holdings Ltd (950.HK) released its Q1 2020 financial report, recording income down 3.5% year-on-year (YOY) to HKD 273 million (USD 35.2 million), and net profits down 15% YOY to HKD 39.9 million (USD 5.2 million). Sales for Lee’s Pharma surgery drugs hemocoagulase and low-molecular-weight heparin calcium decreased 34.8% and 33.1% respectively, as non-emergency surgeries were deprioritized by hospitals due to the COVID-19 pandemic.
Analytics Snapshot

Analytics Snapshot